Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Nanobiotix Announces Selection of NBTX-IV and Collaboration with NCI

Published: Wednesday, June 26, 2013
Last Updated: Wednesday, June 26, 2013
Bookmark and Share
Characterization studies to be undertaken by the US National Cancer Institute’s Nanotechnology Characterization Laboratory.

Nanobiotix has announced the selection of a new product for development, NBTX-IV. It is the second product of the NanoXray pipeline which is designed for systemic administration (intravenous injection).

This product has been selected by the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL) for characterization on the basis of its potential to impact cancer treatment.

NBTX-IV is based on Nanobiotix’s proprietary NanoXray platform. It is designed to be administered intravenously to target deep-seated tumors and lymph nodes which may have been invaded locally by cancer cells.

The product aims to enhance radiotherapy energy to destroy cancer cells and reduce the subsequent escape of malignant cells localized in neighboring tissues cells or lymph nodes. Target indications include lung carcinoma, pancreatic cancer or brain metastases.

As part of the collaboration with NCI, the NCL will perform pre-clinical characterization of NBTX-IV that will support Nanobiotix’s filing of an Investigational New Drug (IND) with the FDA.

In parallel, Nanobiotix will conduct additional preclinical testing to provide a complete dossier for submission.

The NCL was established to investigate the use of nanoparticulate material for the advancement of cancer research and to accelerate the development of promising and safe nanotechnology-derived cancer therapeutics.

It provides preclinical testing and consultation services on a competitive basis to developers, like Nanobiotix, and is working in concert with other US agencies such as the U.S. Food and Drug Administration (FDA) to accelerate the transition of basic nanomedicine research into clinical applications.

“The selection of a second NanoXray product for development coupled with the characterization being undertaken by the NCL is an important strategic step for Nanobiotix,” said Laurent Levy, CEO of Nanobiotix.

Levy continued, “This collaboration with the NCL will hopefully accelerate the pre-clinical development of NBTX-IV, opening the pathway for new clinical indications in addition to the one covered by our first product. The results of the characterization are not only important for our future IND submission, but also raise our profile in the US market.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanobiotix Half Year Results for the Six Months Ended 30 June 2014
Significant operational and clinical progress made.
Tuesday, September 02, 2014
Nanobiotix Sees Clinical Advance in STS Pilot Trial with Lead Product, NBTXR3
Market development plan outlined for earlier potential launch in 2016.
Tuesday, February 11, 2014
NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
NANOBIOTIX announced it has been awarded the “Young Talent” Award at the INVESTOR AWARDS 2013, referring to a newly listed company.
Friday, November 08, 2013
Nanobiotix Announces €2.8 Million Grant to Develop NBTXR3
Through ETPN, Nanobiotix is driving nanomedicine in Europe and is now involved in the first nanomedicine consortium in France with the launch of NICE project.
Friday, July 05, 2013
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with NBTXR3
Second indication for NanoXray product in Head and Neck cancer patients.
Thursday, June 13, 2013
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Influential Cancer Researcher Receives Agilent Thought Leader Award
Biologist Scott Lowe receives award in recognition for his contributions to cancer biology.
Gene-Editing Cures Genetic Blood Disorder in Mice
New technology may offer minimally invasive treatment for genetic disorders of the blood.
New Compound Shows Promise in Treating Multiple Human Cancers
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of all cancers.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
IU Research Reveals Link between Molecular Mechanisms in Prostate Cancer and Ewing's sarcoma
Researchers at IU have suggested that the molecular mechanism that triggers the rare disease Ewing's sarcoma could act as a potential new direction for the treatment of more than half of patients with prostate cancer.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Lab-on-a-Chip to Help Detect Cancer
In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Drug Target for Triple-Negative Breast Cancer Found
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos